Abnormally thick heart muscle disease
Conditions
Interventions
Trimetazidine 20mg three times daily, or placebo 20mg three times daily
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Carrier of HCM associated genetic mutation in the gene encoding for Myosin Heavy Chain 7 (MYH7), Myosin Binding Protein C3 (MYBPC3) or cardiac muscle Troponin T (TNNT2) 18 - 65 years
Exclusion criteria
Exclusion criteria: Cardiovascular disease (in particular HCM defined by maximum wall thickness >15mm), Parkinson disease or parkinsonian symptoms, Renal insufficiency GFR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in mean myocardial energy efficiency after two months of treatment with trimetazidine compared to placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| To study the effect of trimetazidine on: • diastolic function: echocardiography to measure E, A, E/A, E*, E/E* in cm/s • left ventricle and left atrial volume parameters: end-diastolic volume, end-systolic volume, ejection fraction, left ventricular mass, left atrial volume • exercise capacity: duration of exercise, workload • and electrophysiological properties of the heart: ECG to measure PR, QRS, QT interval, ST elevation/depression, heart rate | — |
Countries
Netherlands
Outcome results
None listed